Advanced Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced Renal Cell Carcinoma (RCC) Market Outlook
Thelansis’s “Advanced Renal Cell
Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Advanced Renal Cell Carcinoma (RCC)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Advanced
Renal Cell Carcinoma (RCC) Overview
Renal cell
carcinomas exhibit significant variability in tumor biology and disease
progression, leading to diverse treatment approaches for localized and
metastatic renal cell carcinoma (mRCC). Despite numerous advancements in
systemic therapy, metastatic RCC remains incurable. About one-third of RCC
patients are initially diagnosed with metastatic disease, and a notable portion
of those with localized disease will experience recurrence. Metastasectomy
stands as the standard of care for patients with limited metastatic sites.
Additional FDA approvals have been secured for mRCC, including cabozantinib, a
VEGFR/MET/AXL inhibitor, nivolumab, a programmed death-1 (PD-1) inhibitor, and
lenvatinib, a multikinase inhibitor sanctioned in combination with everolimus.
Several targeted therapies, primarily focusing on vascular endothelial growth
factor (VEGF) or its receptor (VEGFR) and the mammalian target of rapamycin
(mTOR), have been endorsed. VEGF inhibitors such as axitinib, bevacizumab,
pazopanib, sorafenib, and sunitinib, as well as mTOR inhibitors like everolimus
and temsirolimus, are prominent in this therapeutic era.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment